Cargando…
Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator
BACKGROUND: Immune suppression is common in neoplasia and a major driver is tumor-induced myeloid dysfunction. Yet, overcoming such myeloid cell defects remains an untapped strategy to reverse suppression and improve host defense. Exposure of bone marrow progenitors to heightened levels of myeloid g...
Autores principales: | Oliver, Liliana, Alvarez, Rydell, Diaz, Raquel, Valdés, Anet, Colligan, Sean H, Nemeth, Michael J, Twum, Danielle Y F, Fernández, Audry, Fernández-Medina, Olivia, Carlson, Louise M, Yu, Han, Eng, Kevin H, Hensen, Mary L, Rábade-Chediak, Maura L, Fernández, Luis Enrique, Lee, Kelvin P, Perez, Leslie, Muhitch, Jason B, Mesa, Circe, Abrams, Scott I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511656/ https://www.ncbi.nlm.nih.gov/pubmed/36150744 http://dx.doi.org/10.1136/jitc-2022-004710 |
Ejemplares similares
-
Ganglioside containing nano-proteoliposome dampens myeloid-derived suppressor cells function and ability to cross-present tumor antigens: a new approach to recover CTL function on tumor bearing individuals
por: Fernández, Audry, et al.
Publicado: (2013) -
Very small size proteoliposomes abrogate cross-presentation of tumor antigens by myeloid-derived suppressor cells and induce their differentiation to dendritic cells
por: Fernández, Audry, et al.
Publicado: (2014) -
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
por: Märkl, Florian, et al.
Publicado: (2023) -
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022) -
IMMU-10. TUMOR ASSOCIATED MYELOID CELLS DRIVE THE IMMUNOBIOLOGY OF HIGH RISK PEDIATRIC EPENDYMOMA
por: Griesinger, Andrea, et al.
Publicado: (2022)